S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
Flee to Healthcare Stocks if Recession Rears its Head?
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
3 ETFs for the Conservative Investor to Buy and Hold
Stock market today: World shares track Wall Street's slump after Fed says rates may stay high in '24
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Are These Consumer Staples Too Cheap for Investors To Ignore?
A small venture capital player becomes a symbol in the fight over corporate diversity policies
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Markets Are Loving These Stocks 'Firing On All Cylinders'
Etsy Gets an Upgrade and $100 Target...Is the Bottom Finally In?
S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
Flee to Healthcare Stocks if Recession Rears its Head?
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
3 ETFs for the Conservative Investor to Buy and Hold
Stock market today: World shares track Wall Street's slump after Fed says rates may stay high in '24
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Are These Consumer Staples Too Cheap for Investors To Ignore?
A small venture capital player becomes a symbol in the fight over corporate diversity policies
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Markets Are Loving These Stocks 'Firing On All Cylinders'
Etsy Gets an Upgrade and $100 Target...Is the Bottom Finally In?
S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
Flee to Healthcare Stocks if Recession Rears its Head?
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
3 ETFs for the Conservative Investor to Buy and Hold
Stock market today: World shares track Wall Street's slump after Fed says rates may stay high in '24
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Are These Consumer Staples Too Cheap for Investors To Ignore?
A small venture capital player becomes a symbol in the fight over corporate diversity policies
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Markets Are Loving These Stocks 'Firing On All Cylinders'
Etsy Gets an Upgrade and $100 Target...Is the Bottom Finally In?
S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
Flee to Healthcare Stocks if Recession Rears its Head?
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
3 ETFs for the Conservative Investor to Buy and Hold
Stock market today: World shares track Wall Street's slump after Fed says rates may stay high in '24
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Are These Consumer Staples Too Cheap for Investors To Ignore?
A small venture capital player becomes a symbol in the fight over corporate diversity policies
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Markets Are Loving These Stocks 'Firing On All Cylinders'
Etsy Gets an Upgrade and $100 Target...Is the Bottom Finally In?
NASDAQ:PSTI

Pluristem Therapeutics (PSTI) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
N/A
50-Day Range
$1.00
▼
$1.58
52-Week Range
N/A
Volume
2,128 shs
Average Volume
715,259 shs
Market Capitalization
$32.35 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media

PSTI stock logo

About Pluristem Therapeutics (NASDAQ:PSTI) Stock

Pluristem Therapeutics Inc. operates as a bio-technology company. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trial for the recovery after surgery for hip fracture; in Phase II clinical trail for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18, which has completed Phase I clinical trial incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various animal studies for the evaluation of PLX-R18 for the treatment of acute radiation syndrome. The company has a license agreement for conducting clinical trials of PLX-PAD product in South Korea. It also has a collaborative project nTRACK, that examines gold nano particles labeling of stem cells; and has collaboration agreement with the NASA's Ames Research Center to evaluate the potential of PLX cell therapies in preventing and treating medical conditions caused during space missions. Pluristem Therapeutics Inc. was incorporated in 2001 and is based in Haifa, Israel.


PSTI Stock News Headlines

August 18, 2023 | seekingalpha.com
NBRVF Nabriva Therapeutics plc
July 25, 2022 | finance.yahoo.com
Pluri CEO Issues Shareholder Update
September 21, 2023 | Wall Street Fundamentals (Ad)
How is This "Hidden Gem" Thriving in a Turbulent Market?
While Wall Street flounders and giants like Amazon & Microsoft lay off thousands... One overlooked company has been quietly achieving over 400% growth. How? By buying, building, and scaling a portfolio of promising brands in high-margin, recession-resistant verticals.
July 25, 2022 | benzinga.com
Pluristem Therapeutics Inc. Changes its Name to "Pluri Inc." Reflecting the Company's Strategy to Leverage its Innovative 3D Cell-based Technology Platform to Additional Industries
July 25, 2022 | finance.yahoo.com
Pluristem Therapeutics Inc. Changes its Name to “Pluri Inc.” Reflecting the Company’s Strategy to Leverage its Innovative 3D Cell-based Technology Platform to Additional Industries
July 14, 2022 | finance.yahoo.com
Pluristem (PSTI) Phase III Study Misses Goal, Stock Down
July 13, 2022 | finance.yahoo.com
Pluristem Posts Mixed Results From Study Of Muscle Regeneration After Hip Fracture Surgery
July 13, 2022 | markets.businessinsider.com
Pluristem's Phase 3 Study Of PLX-PAD To Treat Muscle Injury Does Not Meet Primary Goal
September 21, 2023 | Edge On The Street (Ad)
Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
July 13, 2022 | finance.yahoo.com
Pluristem Reports Topline Results from its Phase III Study of Muscle Regeneration Following Hip Fracture Surgery
May 10, 2022 | apnews.com
Pluristem: Fiscal Q3 Earnings Snapshot
March 28, 2022 | finance.yahoo.com
Pluristem and Tnuva to Ring Nasdaq Closing Bell in Honor of New Partnership
March 23, 2022 | seekingalpha.com
Pluristem PLX-R18 shows promise in blood cell recovery in cell transplant patients in trial
March 23, 2022 | finance.yahoo.com
Pluristem Releases PLX-R18 Hematology Phase I Study Results: Data Show Increase in All Blood Lines and Reduction in Blood Transfusions
March 21, 2022 | nasdaq.com
Pluristem Therapeutics, Inc. Common Stock (PSTI)
March 8, 2022 | finance.yahoo.com
Pluristem and Tnuva Appoint Food Tech Veteran Eyal Rosenthal as Chief Executive Officer of their New Joint Venture
February 24, 2022 | finance.yahoo.com
Pluristem Announce the Closing of its Collaboration with Tnuva Group to Establish Cultured Food Platform
January 12, 2022 | marketwatch.com
Thinking about buying stock in Pluristem Therapeutics, DiDi Global, Robinhood Markets, Bitfarms, or Adamis Pharmaceuticals?
January 10, 2022 | msn.com
Israel's Tnuva partners with Pluristem to develop cultured cell-based meat
January 10, 2022 | finance.yahoo.com
Biotech Pluristem, Israel-Based Tnuva Collaborate On Cultured Food Platform
January 10, 2022 | nasdaq.com
Pluristem Climbs On Collaboration With Tnuva Of Israel For Commercialization Of Alternative Meat
January 10, 2022 | seekingalpha.com
Pluristem jumps 31% on collaboration with Tnuva to develop cultured cell-based food products
January 10, 2022 | finance.yahoo.com
Biotechnology Company Pluristem, and Israel’s Largest Food Producer Tnuva, Launch Landmark Collaboration to Establish Cultured Food Platform
December 30, 2021 | nasdaq.com
Pluristem Therapeutics Inc Shares Fall 3.3% Below Previous 52-Week Low - Market Mover
December 29, 2021 | marketwatch.com
Pluristem Therapeutics Shares Tumble on Covid-19 Study Failure >PSTI
December 28, 2021 | finance.yahoo.com
Pluristem (PSTI) Misses Study Goal to Treat COVID-Related ARDS
December 27, 2021 | nasdaq.com
Pluristem: Phase II Studies Of ARDS Associated With COVID-19 Fails To Meet Primary Efficacy Endpoint
See More Headlines
Receive PSTI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pluristem Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

PSTI Company Calendar

Last Earnings
11/08/2021
Today
9/21/2023
Fiscal Year End
6/30/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological Products, Except Diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PSTI
CUSIP
N/A
CIK
1158780
Web
www.pluristem.com
Phone
972747107171
Fax
972-74-710-8787
Employees
153
Year Founded
2003

Profitability

EPS (Most Recent Fiscal Year)
($1.47)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-49,870,000.00
Net Margins
N/A
Pretax Margin
-20,024.79%
Return on Equity
-100.63%
Return on Assets
-55.46%

Debt

Debt-to-Equity Ratio
0.57
Current Ratio
8.22
Quick Ratio
8.22

Sales & Book Value

Annual Sales
$20,000.00
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.80 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
32,348,000
Free Float
30,601,000
Market Cap
$32.35 million
Optionable
Optionable
Beta
1.91

Social Links

7 Stocks to Buy And Hold Forever Cover
7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Mr. Yaacov Yanay (Age 51)
    Pres, CEO & Director
    Comp: $612.6k
  • Ms. Chen Franco-Yehuda (Age 38)
    CFO, Treasurer & Sec.
    Comp: $330.3k
  • Mr. Lior Raviv
    Chief Technology Officer
  • Ms. Efrat Livne-Hadass
    VP of HR
  • Dr. Nitsan Halevy M.D.
    Chief Medical Officer
  • Mr. Nimrod Bar Zvi
    Chief Commercial Officer

Key Competitors

View All Competitors













PSTI Stock - Frequently Asked Questions

How were Pluristem Therapeutics' earnings last quarter?

Pluristem Therapeutics Inc. (NASDAQ:PSTI) posted its earnings results on Monday, November, 8th. The biotechnology company reported ($0.36) EPS for the quarter, beating analysts' consensus estimates of ($0.41) by $0.05.

When did Pluristem Therapeutics' stock split?

Pluristem Therapeutics's stock reverse split on the morning of Thursday, July 25th 2019. The 1-10 reverse split was announced on Wednesday, July 24th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, July 24th 2019. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of Pluristem Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pluristem Therapeutics investors own include Teva Pharmaceutical Industries (TEVA), NVIDIA (NVDA), Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Novavax (NVAX), Protalix BioTherapeutics (PLX), Micron Technology (MU), Pfizer (PFE), SCYNEXIS (SCYX) and Advanced Micro Devices (AMD).

What is Pluristem Therapeutics' stock symbol?

Pluristem Therapeutics trades on the NASDAQ under the ticker symbol "PSTI."

How much money does Pluristem Therapeutics make?

Pluristem Therapeutics (NASDAQ:PSTI) has a market capitalization of $0.00 and generates $20,000.00 in revenue each year. The biotechnology company earns $-49,870,000.00 in net income (profit) each year or ($1.47) on an earnings per share basis.

How many employees does Pluristem Therapeutics have?

The company employs 153 workers across the globe.

How can I contact Pluristem Therapeutics?

Pluristem Therapeutics' mailing address is MATAM ADVANCED TECHNOLOGY PARK BUILDING NO. 5, HAIFA L3, 3508409. The official website for the company is www.pluristem.com. The biotechnology company can be reached via phone at 972747107171, via email at danar@pluristem.com, or via fax at 972-74-710-8787.

This page (NASDAQ:PSTI) was last updated on 9/21/2023 by MarketBeat.com Staff

My Account -